Psych MEQs / SAQs · Consultation-liaison psychiatry
Stroke psychiatry — PSD, location myth, capacity (MEQ)
FRANZCP-style MEQ on post-stroke depression, Carson location myth, SSRI monitoring with dual antiplatelets, FLAME vs FOCUS/AFFINITY/EFFECTS, and decision-specific capacity.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Formulation and location. Concurrent post-stroke depression (depressive disorder due to another medical condition): anhedonia, insomnia, passive SI, rehab withdrawal at 6 weeks — PSD affects roughly one-third of survivors at some point and worsens participation.[1][2] Correct the junior doctor: lesion location alone is not a reliable diagnostic determinant of PSD (Carson systematic review); left frontal history is teaching colour, not a rule that makes clinical assessment unnecessary.[3][7] Distinguish from pure apathy or emotionalism if features fit, but here depressive syndrome is primary.
(ii) Assessment. Stroke dossier (territory, disability, dual antiplatelets), collateral, aphasia-adapted MSE, suicide risk, medical drivers of non-engagement, cognitive screen. PHQ-type tools if language allows; otherwise observational/therapy metrics.[1][7]
(iii) Treatment. Multimodal AHA/ASA-aligned care: rehab psychology/behavioural activation adapted for aphasia; social support; treat pain/sleep.[1] Antidepressant example: sertraline 25–50 mg oral daily titrate, or escitalopram 5–10 mg oral daily (often 5 mg if older/frail), monitoring bleeding with dual antiplatelets, sodium, falls, QTc (especially escitalopram/citalopram), and early suicide risk; Cochrane supports pharmacological and psychological treatment options with evidence-quality caveats.[6][7] Trial literacy: Robinson JAMA 2008 showed prevention with escitalopram or problem-solving therapy in non-depressed patients — different question from treating established PSD.[4] Do not start fluoxetine solely for motor recovery; after FLAME enthusiasm, large pragmatic trials (FOCUS and related AFFINITY/EFFECTS programme) do not support routine fluoxetine for functional outcome — treat mood on psychiatric grounds.[5]
(iv) Capacity and disposition. House sale is a high-stakes, decision-specific capacity problem: test understanding, retention, weighing, communication with speech support. Nodding or mild aphasia does not prove valid weighing, especially with depression-related hopelessness. Pause major transactions; involve social work/legal substitute pathways under local law; reassess after mood treatment. Disposition: suicide safety plan, stepwise rehab, community CL/GP follow-up, secondary prevention adherence support.[1][7]
Common errors
Equating left frontal lesion with automatic PSD diagnosis; prescribing fluoxetine only for the hemiparetic arm; ignoring bleeding/hyponatraemia; equating aphasia with global incapacity; omitting suicide risk.[3][5][1]
Examiner notes
Reward myth correction (Carson), named prevention RCT (Robinson 2008), SSRI practical dosing with antithrombotic caution, FOCUS-level trial literacy, and sophisticated capacity reasoning.[3][4][5]
References
- [1]Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, et al. Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke, 2017.PMID 27932603
- [2]Hackett ML, Pickles K Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies Int J Stroke, 2014.PMID 25117911
- [3]Carson AJ, MacHale S, Allen K, Lawrie SM, et al. Depression after stroke and lesion location: a systematic review Lancet, 2000.PMID 10963248
- [4]Robinson RG, Jorge RE, Moser DJ, Acion L, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial JAMA, 2008.PMID 18505948
- [5]FOCUS Trial Collaboration Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial Lancet, 2019.PMID 30528472
- [6]Allida SM, Hsieh CF, Cox KL, Patel K, et al. Pharmacological, non-invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke Cochrane Database Syst Rev, 2023.PMID 37417452
- [7]Robinson RG, Jorge RE Post-Stroke Depression: A Review Am J Psychiatry, 2016.PMID 26684921